FDA authorizes pharmacists to prescribe Pfizer's COVID-19 pill

Pfizer's Paxlovid has been proven to curb the worst effects of COVID-19 in patients

NEWYou can now listen to Fox News articles!

The Food and Drug Administration (FDA) announced Wednesday that it would authorize state-licensed pharmacists to prescribe Pfizer's Paxlovid for eligible patients. 

"Since Paxlovid must be taken within five days after symptoms begin, authorizing state-licensed pharmacists to prescribe Paxlovid could expand access to timely treatment for some patients who are eligible to receive this drug for the treatment of COVID-19," Patrizia Cavazzoni, M.D., director for the FDA’s Center for Drug Evaluation and Research, said in an FDA statement Wednesday

State-authorized pharmacists are now able to screen patients if they are eligible for the COVID-19 pill per specifications outlined by the FDA. Prior to the FDA announcement, only physicians were able to prescribe the drug. 

Pfizer's Paxlovid is currently authorized for the treatment of "mild-to-moderate COVID-19." The antiviral drug has been proven to curb the worst effects of the disease, showing positive results of direct viral testing for those at high risk of progressing to severe COVID-19, according to the FDA. 

FDA WANTS COVID-19 BOOSTERS TARGETING OMICRON BA.4, BA.5 SUBVARIANTS

FILE - This Friday, Feb. 5, 2021 file photo shows the Pfizer logo displayed at the company's headquarters in New York.

FILE - This Friday, Feb. 5, 2021 file photo shows the Pfizer logo displayed at the company's headquarters in New York. ((AP Photo/Mark Lennihan))

The FDA stated that those considered "eligible" to be prescribed the medication would need to present "a positive home test result from a rapid antigen diagnostic test, or a positive PCR test, to their provider."

Medical syringes and FDA logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. 

Medical syringes and FDA logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021.  (Jakub Porzycki/NurPhoto via Getty Images)

BA.5 is currently the dominant subvariant of the coronavirus in the U.S., making up 53.6% of cases nationwide, according to the Centers for Disease Control and Prevention (CDC). Since fewer states are releasing new data, the accurate number of cases across the country remains unclear. The New York Times reported that only 23 states are continuing to release new data. 

BA.5 BECOMES DOMINANT US OMICRON SUBVARIANT

The FDA is pushing vaccine makers to target BA.4 and BA.5 in their updated shots as they prepare for fall cases.  

A customer walks into a CVS Pharmacy store, Tuesday, Aug. 3, 2021, in Woburn, Mass.

A customer walks into a CVS Pharmacy store, Tuesday, Aug. 3, 2021, in Woburn, Mass. ((AP Photo/Charles Krupa, File))

Fox News reached out to the CDC and the White House's Office of Science and Technology Policy for comment but did not hear back in time for publication. 

CLICK HERE TO GET THE FOX NEWS APP

The Associated Press contributed to this report.